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Purpose: Although nodal metastasis is the most powerful prognostic factor in rectal cancer, marked heterogeneity exists 
within stage III rectal cancer. Recent studies of rectal cancer have shown a prognostic superiority of the lymph node ratio 
(LNR) compared with N stage. The purpose of this study was to investigate the prognostic value of the LNR in the era of 
the 7th edition of the TNM classification.
Methods: We included 190 patients who underwent a curative resection for rectal cancer with nodal metastasis. The patients 
were divided into four groups on the basis of statistically calculated cut-off values as 0.21, 0.32, and 0.61.
Results: The LNR was an independent risk factor for overall survival (OS; P = 0.008) and for systemic recurrence-free sur-
vival (SRFS; P = 0.002). However, the LNR was not a predictive factor for local recurrence. When the N stage of the sixth 
TNM staging system was separately analyzed as a covariate, the LNR was also found to be a predictive factor for both OS 
and SRFS (P = 0.012 and P = 0.004, respectively). A LNR value of 0.21 offered the best cut off to separate patients into two 
prognostic groups. 
Conclusion: The defined cut-off values of the LNR were an independent risk factor for OS and distant metastasis-free sur-
vival in patients with rectal cancer, irrespective of the sixth or the seventh version of the TNM classification, and the LNR 
should be considered as a prognostic variable in any future staging system.
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and does not reflect the number of investigated lymph nodes, to 
which a correlation with survival of colorectal cancer has been re-
ported [7, 8].
The metastatic LN ratio (LNR), which can be classified with one 
to three cut-off values, is a significant prognostic factor for survival 
in stage III colon cancer, and its role as prognosticator has been 
reported to more valuable than that of the existing lymph node 
staging [9-11]. This prognostic value of the LNR in colon cancer 
is also reported in rectal cancer as a risk factor for mortality and 
recurrence [12, 13]. A multicenter study reported a significant cor-
relation between the LNR and survival in rectal cancer [14].
However, previous studies on the LNR in rectal cancer selected 
cut-off points arbitrarily [12] or included only patients undergo-
ing sphincter-preserving surgery [13] or patients with over 70% 
pelvic sidewall lymph node dissection [14]; therefore, the bias could 
have been in the patient selection. In addition, the studies had a 
limitation of methodology in that the clinical value of the LNR was 
analyzed by comparing N staging divided into two groups with 
the LNR divided into four groups [12, 14]. For that reason, we di-
vided stage III rectal cancer patients by using cut-off points of the 
LNR determined through statistical methods and analyzed the 
INTRODUCTION
The prognosis of rectal cancer is still poor, with a survival rate of 
around 60% and a local recurrence rate of approximately 10% [1-3]; 
therefore, many efforts to identify prognostic factors have contin-
uously been made to improve the prognosis. Although one of the 
most critical prognostic factors is the status of lymph node metas-
tasis [4, 5], the survival rate of stage III rectal cancer at the same 
stage varies [4, 6], showing its limitations in reflecting the progno-
sis. In addition, the existing LN staging of rectal cancer (N stag-
ing) is based on only the number of metastatic lymph nodes [4, 6] 
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prognostic factors by using the TNM staging in the sixth [15] and 
the seventh [6] editions, respectively, to investigate the clinical value 
of the LNR in rectal cancer with lymph node metastasis.
METHODS
Patients
This study recruited 299 patients undergoing a proctectomy for 
rectal cancer within 10 cm from the anal verge measured with pre-
operatively rigid sigmoidoscopy or colonoscopy at Pusan Paik Hos-
pital from January 1995 to December 2004. We excluded 100 pa-
tients with negative lymph node metastasis, distant metastasis 
found at diagnosis, history of preoperative adjuvant therapy and 
remaining local residual cancer left. We also excluded nine patients 
using postoperative adjuvant chemotherapy other than 5-fluoro-
uracil (5-FL) or not being followed up, so 190 patients were finally 
included in this study. All surgery was performed by one surgeon, 
and it was open surgery based on a total mesorectal excision. An 
abdominoperineal resection was performed when the tumor dis-
tance was less than 4 cm from anal verge, invasion of the pelvic 
floor muscle caused by the tumor was suspected during the sur-
gery or the distal resection margin was threatened by the tumor.
A combination of chemotherapy and radiotherapy was provided 
postoperatively, and its indication was patients with an involvement 
of the circumferential resection margin. However, it was option-
ally done when the number of metastatic lymph nodes was one to 
three in the postoperative pathological examination or when the 
patients were over 75 years or had heart disease. The postopera-
tive adjuvant chemotherapy started within 2-4 weeks after the sur-
gery and was given “Mayo regimen” for 5 days every month by 
bolus infusing 5-FL and leucovorin six times or by orally admin-
istering 5-FL for the elderly. Radiotherapy began on the first day of 
the third cycle of intravenous chemotherapy and at around four 
weeks after the surgery for the oral administration of chemother-
apy. Fractionated irradiation of the whole pelvic cavity with a dose 
of 4,500-5,000 cGy was conducted. When the dose of intravenously 
administered chemotherapy and the dose of planned radiother-
apy were accomplished fully, the patient was considered to have 
completed chemoradiation therapy.
After assessing the proximal resection margin, the distal resec-
tion margin, the integrity of the meorectal fascia, and the metastatic 
lymph nodes of the resected specimen through gross examination 
by the surgeon in the operating room, specimen was sent to pa-
thology. The samples were fixed in 10% formalin solution for 24 
hours, and lymph nodes were collected by dissecting them through 
manual palpation to examine lymph nodes of the mesorectum 
around the primary lesion and the proximal mesorectum. Special 
techniques, such as the fat-clearing method, were not used in the 
dissection of lymph nodes. Tissues showing firm texture under dig-
ital compression during the collection of lymph nodes were thought 
to be lymph nodes; lymph nodes with sizes of more than 3 mm 
were sectioned along the longitudinal axis, and those with sizes of 
less than 3 mm were used as a whole for hematoxilin-eosine stain-
ing and paraffin section manufacturing.
Lymph node staging
Lymph node stages were classified into N1 and N2 based on the 
sixth edition of the classification of the American Joint Commit-
tee on Cancer (AJCC) by using the number of metastatic lymph 
nodes and into N1a, N1b, N2a and N2b based on its seventh edi-
tion. To investigate the prognosis by the LNR of the number of 
metastatic lymph nodes to the number of collected and examined 
lymph nodes, its cut-off values were determined to be 0.21, 0.32, 
and 0.61 through recursive partitioning [16] using R 2.2.1 (R De-
velopment Core Team, Vienna, Austria). The patients were classi-
fied into four groups with the three cut-off values: group 1 (LNR1, 
n = 74) for LNRs of less than 0.21; group 2 (LNR2, n = 25) for 
LNRs of 0.21-0.32; group 3 (LNR3, n = 56) for LNRs of 0.32-0.61; 
and group 4 (LNR4, n = 35) for LNRs of over 0.61.
Follow-up and survival analysis
Postoperative follow-up included physical examination and blood 
tests such as serum carcinoembryonic antigen every three months 
for first 2 years and every six months, after 2 years respectively. Ra-
diologic examination, like abdominopelvic computerized tomog-
raphy (CT), chest X-ray and chest CT, was performed every six or 
twelve months for the first two years and then every 12 months.   
If any suspicious lesion was found on radiologic examination, a 
bone scan and positron emission tomography were additionally 
performed.
Local recurrence was defined as a recurrence newly found in the 
pelvic cavity or the perineum in the postoperative follow-up and 
confirmed by biopsy or by a continuous increase of the size in the 
radiologic examinations conducted at intervals of 3-6 months. Sys-
temic recurrence of the disease was defined pathologically or on 
the basis of radiologic findings during follow-up. If the serum car-
cinoembryonic antigen level became higher but there was no abnor-
mality on radiologic examination, the patient was not considered 
as having a recurrence. The period to recurrence or of survival was 
calculated from the date of surgery for rectal cancer to the date of 
the last visit to the outpatient clinic or the date of death. If recurrence 
was not observed by the last follow-up, regardless of death, the case 
was considered as no recurrence. Deaths due to causes other than 
rectal cancer were considered as deaths in the survival analysis.
Statistical analysis
Statistical analysis was performed with SPSS ver. 12.0 (SPSS Inc., 
Chicago, IL, USA). The means of the groups were compared with 
one-way ANOVA, and chi-squared test and Fisher’s exact tests were 
used to compare the frequencies of the four LNR groups with the 
clinicopathological variables. The Kaplan-Meier method was used 
to estimate the rates of survival and recurrence. Log rank tests were 
used to compare patient groups with respect to the estimated sur-
vival and recurrence curves. For independent prognostic factors, Journal of The Korean Society of
Coloproctology
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a multivariate analysis using the Cox regression model was used to 
determine factors influencing recurrence and death. Factors with 
a P-value of less than 0.1 in the univariate analysis were included 
in the multivariate analysis. A P-value of less than 0.05 was con-
sidered to be statistically significant. By considering that N stages 
of TNM staging, two groups in the sixth edition and four groups 
in the seventh edition, the LNRs were also classified into two and 
four groups, respectively, and the two groups and the four groups 
of the N staging and the LNR were compared in the multivariate 
analysis for a more objective statistical analysis.
RESULTS
Comparison of the characteristics of the subjects and 
variables
The median age of the patients was 57.0 years (range, 29 to 81 years) 
and the median follow-up period was 55 months (range, 6 to 145 
months). Eighteen (9.4%) patients were followed up for less than 
five years. The median number of lymph nodes retrieved was 12 
(range, 2 to 52), and the median number of metastatic lymph nodes 
was 3 (range, 1 to 32) (Table 1). The number of the collected lymph 
nodes was inversely correlated to the LNR (r = -0.085), but the 
correlation was not statistically significant (P = 0.245) (Fig. 1). Al-
though the four groups divided through recursive partitioning did 
not show any significant differences in comparison of rates with 
various clinicopathological variables, LNR4 had higher rates of N2 
and N2b (P = 0.000), and LNR1 had relatively higher rates of N1 
and N1a, respectively, in the sixth and the seventh editions (P = 
0.000). Histologic differentiation of LNR3 and LNR4 showed sig-
nificantly lower grades compared to LNR1 and LNR2 (P = 0.009), 
and the proportions of patients with postoperative adjuvant ther-
apy were not different among the groups divided by LNR (P = 
0.361) (Table 2).
Oncologic outcomes
Thirty-four (18.5%) patients had a local recurrence, and 78 (41.0%) 
developed systemic recurrence during the follow-up period. Six-
teen patients developed both local and systemic recurrence, and 
90 (42.3%) died during follow-up. In the univariate analysis, N stag-
ing in the sixth and the seventh editions, LNR and preoperative 
carcinoembryonic antigen level were significant factors of survival 
and systemic recurrence, and only N staging in the seventh edi-
Table 1. Characteristics of the patients in this study
Variables
Age (yr)  57.0 (29-81) 
Gender (M:F)  1.04:1
Follow-up duration (mo) 55.0 (6-145) 
Tumor location from anal verge (cm)
   0-5   66 (34.7)
   5.1-10 124 (65.3)
Operative method
   Abdominoperineal resection   77 (40.5)
   Sphincter-saving operation 113 (59.5)
T stage 
   T1, 2 15 (7.8)
   T3, 4 175 (92.2)
N stage 
   N1 107 (56.3)
   N2   83 (43.7)
   N1a
a   56 (29.5)
   N1b
a   51 (26.8)
   N2a
a   42 (22.1)
   N2b
a   41 (21.6)
Lymphatic duct invasion
   Present   61 (32.1)
   Absent 129 (67.9)
Extramural venous invasion
   Present   27 (14.2)
   Absent 163 (85.8)
Carcinoembryonic antigen (ng/mL) > 5
b   56 (31.2)
Tumor grade
   High 16 (8.4)
   Low or medium 174 (91.6)
Chemoradiation 114 (60.0)
LN resected
   No. of lymph node examined   12 (2-52)
   No. of lymph node positive     3 (1-32)
Values are presented as median (range) or number (%).
aBased on 7th edition of TNM staging. 
bBased on data available on 179 patients.
Fig. 1. Correlation between lymph node (LN) examined and lymph 
node ratio (LNR).
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tion and LNR classified into two groups were significant factors of 
local recurrence. N staging in the sixth edition, LNR divided into 
four groups and the preoperative carcinoembryonic antigen level 
did not affect local recurrence significantly (Table 3). The five-year 
survival rate and the five-year systemic recurrence rate of LNR4 
were 31.3% and 61.0%, respectively, compared to those of LNR1, 
72.0% and 26.0%, respectively (P = 0.001, P = 0.016). In the mul-
tivariate analysis, the risks of death and systemic recurrence were 
3.9 times (95% confidence interval [CI], 2.16 to 7.16) and 2.9 times 
(95% CI, 1.58 to 3.33) higher in LNR4 than in LNR1, respectively, 
and the risk factors for death and systemic recurrence were found 
to be the preoperative carcinoembryonic antigen level and the LNR 
classified into two groups or into four groups. Neither N staging 
based on the sixth nor on the seventh edition were independent 
risk factors (Table 4). Univariate analysis revealed that there was 
interaction between LNR and retrieval of less than 12 lymph nodes 
in relation to survival and to systemic recurrence (Figs. 2, 3).
DISCUSSION
Lymph node metastasis is well known to be one of the most im-
portant prognostic factors in colorectal cancer. However, as the on-
cologic significance of the number of retrieved lymph nodes [7, 8] 
has increased, some have pointed out that the current N staging, 
Table 2. Comparison of the characteristics of patients by lymph node ratio (LNR)
Variables LNR1 (n = 74) LNR2 (n = 25) LNR3 (n = 56) LNR4 (n = 35) P-value
Age (yr) 59.0 (34-81) 60.0 (31-80) 56.0 (35-73) 54.0 (29-79) 0.160
Gender (M:F) 35:39 15:10 28:28 19:16 0.708
Tumor location from anal verge (cm) 0.377
   0-5 26 (35.1) 11 (44.0) 16 (23.6) 13 (37.1)
   5.1-10 48 (64.9) 14 (56.0) 40 (70.4) 22 (62.9)
Operative method 0.359
   Abdominoperineal resection 30 (40.5) 12 (48.0) 16 (32.1) 17 (48.6)
   Sphincter-saving operation 44 (59.5) 13 (52.0) 40 (67.9) 18 (51.4)
T stage 0.375
   T 1,2 7 (9.5) 2 (8.0) 4 (7.1) 2 (5.7)
   T 3,4 67 (90.5) 23 (92.0) 52 (92.9) 33 (94.3)
N stage
   N1 71 (95.9) 14 (56.0) 19 (35.7) 3 (8.6) 0.000
   N2 3 (4.1) 11(44.0) 37 (64.3) 32 (91.4)
   N1a
a 49 (69.1) 4 (16.0) 3 (15.8) 0 (0.0) 0.000
   N1b
a 22 (26.8) 10 (40.0) 16 (28.6) 3 (8.6)
   N2a
a 3 (4.1) 11(44.0) 23 (46.8) 5 (14.3)
   N2b
a 0 (0.0) 0 (0.0) 14 (25.0) 27 (77.1)
Lymphatic duct invasion 0.080
   Present 21 (23.4) 4 (16.0) 20 (35.7) 16 (45.7)
   Absent 51 (76.6) 21 (84.0) 36 (64.3) 19 (54.3)
Extramural venous invasion 0.238
   Present 3 (4.1) 4 (16.0) 8 (14.3) 7 (20.0)
   Absent 71 (95.9) 21 (84.0) 48 (85.7) 28 (80.0)
Carcinormbryonic antigen (ng/mL) > 5 25 (61.4) 16 (54.3) 16 (63.8) 11 (45.5) 0.314
Tumor grade 0.009
   High 3 (4.1) 1 (4.0) 5 (8.9) 7 (20.0)
   Low or medium 71 (95.9) 24 (96.0) 51 (91.1) 28 (80.0)
Chemoradiation 50 (67.6) 15 (60.0) 30 (53.6) 19 (55.3) 0.351
Data are presented as median (range) or number (%) unless otherwise indicated.
aBased on 7th edition of TNM staging.Journal of The Korean Society of
Coloproctology
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which depends on the number of metastatic lymph nodes [4, 6], 
cannot reflect the prognosis accurately. Furthermore, the number 
of retrieved lymph nodes is a variable affected by numerous fac-
tors [17], so a prognostic classification system to minimize the in-
fluence of the number of collected lymph nodes and to supplement 
the limitations of N staging is necessary for postoperative adju-
vant therapy and close follow-up in stage III colorectal cancer pa-
tients. In addition, because the survival rate of stage III colorectal 
cancer varies widely [4, 6, 18], the clinical role of the LNR as a bi-
ologic predictor of prognosis has been demonstrated [9-14].
Previous studies on the LNR for rectal cancer [12, 14, 19] deter-
mined cut-off values based on quartiles or complex statistical meth-
ods used, so the results had limitations in applications to clinical 
practice. Thus, we identified the cut-off values for the prognostic 
stratification by using recursive partitioning [20], which could sta-
tistically calculate the cut-off values for the stratification of the prog-
nostic groups in a relatively simple manner. In addition, previous 
studies on colorectal cancer [9-14] reporting the prognostic supe-
riority of the LNR compared to current N staging have limitations 
of bias in the statistical analysis and the methodology. Therefore, 
we classified the LNR into two groups and four groups, respectively, 
and N staging into the two and the four groups, respectively, and 
used them as covariates, as categorical variables in multivariate anal-
ysis, to investigate whether the LNR or N staging was more effec-
tive in reflecting the prognosis. In this study, the LNR was found 
to be an independent factor increasing risk of death and systemic 
recurrence regardless of the method of N substaging, which means 
that the prognostic stratification of the LNR was superior to that 
of N staging. Our results were similar to those in a report by De 
Ridder et al. [11] demonstrating that the LNR had better ability to 
Table 3. Univariate analysis of the risk factors
Variables
5-yr OS 5-yr SRFS 5-yr LRFS
 % P-value  % P-value  % P-value
Gender
   Male 52.8 0.561 59.7 0.773 83.7 0.921
   Female 54.8 58.3 77.5
Tumor height (cm)
   0-5 54.3 0.784 62.7 0.309 77.7 0.781
   5.1-10 56.6 57.4 81.4
Operative method
   APR 58.1 0.667 61.2 0.466 81.6 0.532
   SSO 50.6 57.7 78.4
T stage
   T 1, 2 73.3 0.071 79.4 0.080 92.3 0.142
   T 3, 4 51.9 57.2 78.2
N stage
   N1 66.2 0.001 68.1 0.009 81.6 0.366
   N2 38.0 47.2 77.8
   N1
a 76.1 0.000 77.4 0.004 84.9 0.094
   N1
b 54.8 57.7 85.5
   N2
a 41.7 57.3 77.2
   N2
b 34.1 36.7 65.4
Lymph node ratio
   LNR1
a 72.9 0.000 73.8 0.002 88.6 0.014
   LNR2 44.3 49.5 73.8
   LNR1
b 72.0 0.001 74.0 0.016 88.6 0.060
   LNR2 47.7 63.7 74.2
   LNR3 46.6 51.1 75.5
   LNR4 31.3 39.0 73.5
 (continued to the next page)Journal of The Korean Society of
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Table 3. (continued from the previous page) Univariate analysis of the risk factors
Variables
5-yr OS 5-yr SRFS 5-yr LRFS
 % P-value  % P-value  % P-value
No. of LN examined
   >12 53.8 0.722 61.0 0.538 77.3 0.370
   <12 53.6 56.6 82.2
CRT
c
   Complete 56.7 0.348 61.5 0.981 81.6 0.748
   Incomplete 51.1 57.1 78.2
CEA (ng/mL)
d
   ≤5 66.9 0.000 69.1 0.000 82.8 0.064
   >5 30.2 40.8 74.1
Lymphatic duct invasion
   Present 57.3 0.719 62.2 0.481 74.0 0.435
   Absent 52.2 57.7 82.6
Extramural venous invasion
   Present 44.1 0.295 61.0 0.401 78.7 0.377
   Absent 55.9 47.0 85.0
Distal resection margin (cm)
e
   >1  52.5 0.667 60.7 0.822 80.8 0.181
   <1  53.5 57.2 82.9
   Close
f 34.1 37.4 56.1
Tumor grade
   High 55.8 0.295 54.1 0.445 87.5 0.741
   Low or medium 49.2 59.6 78.9
OS, overall survival; SRFS, systemic recurrence-free survival; LRFS, local recurrence-free survival; APR, abdominoperineal resection; SSO, sphincter-saving operation in-
cluding Hartmann’s procedure; LNR, lymph node ratio; LN, lymph node; CRT, chemoradiation; CEA, carcinoembryonic antigen.
Cut-off values were 
a0.21 and 
b0.21,0.32, and 0.61. 
cCompleteness of CRT was defined as intended doses of radiation and chemotherapy given, 
d11 patients in whom 
serum CEA level was not measured were excluded from the analysis. 
eOnly the patients with SSO were included in the analysis. 
fThe distal clearance margin of 2 mm or 
less whereas the margin was microscopically uninvolved.
Table 4. Multivariate analysis of survival and systemic recurrence-free survival
Variables Category
Overall survival Systemic recurrence-free survival
Adjusted HR (95% CI) P-value Adjusted HR (95% CI) P-value
CEA level (ng/mL) ≤5 1 0.000 1 0.000
>5 2.89 (1.84-4.54) 3.21 (2.00-5.16)
LNR
a 1 1 0.012 1 0.004
2 2.07 (1.11-3.77) 2.20 (1.28-3.56) `
LNR
b 1 1 0.008 1 0.002
2 2.27 (1.29-4.02) 1.65 (0.83-2.29)
3 2.48 (1.27-4.84) 2.20 (1.19-3.20)
4 3.94 (2.16-7.16) 2.94 (1.58-3.33)
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; LNR, lymph node ratio. 
aA single cut-off point (0.21) 
bthree cut-off points (0.21,0.32, and 0.61) were selected for substaging based on a recursive partitioning procedure.Journal of The Korean Society of
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discriminate prognosis groups by dividing the LNR and N stages 
into two groups, respectively, only in colon cancer.
Given the hypothesis of Rinkus et al. [21] that preoperative ad-
juvant therapy could raise the absolute value of the LNR by reduc-
ing the number of collected lymph nodes, it seems to rational to 
exclude patients from receiving neoadjuvant therapy to decrease 
the possibility of neoadjuvant therapy influencing the LNR. More-
over, a previous studies [13, 14] on the LNR in patients with low 
rectal cancer found that the LNR had an oncologic significance, 
but those results should be carefully interpreted due to limitations 
in patient selection. However, considering this study included the 
patients who were not treated with neoadjuvant treatment, our 
results might provide clinical data on treatment of stage III mid 
and low rectal cancer although its number of subjects is small and 
it utilizes a retrospective study design.
One of the major limitations in previous studies on the LNR was 
the subjective determination of cut-off values, which was pointed 
out by Ceelen et al. [22]. Thus, we used recursive partitioning, as 
mentioned above, to determine the cut-off values in a more objec-
tive and useful manner [16, 20] and selected a single reference 
point, 0.21, for the prognostic classification. Dekker et al. [19] re-
porting the oncologic impact of the LNR in rectal cancer patients 
receiving neoadjuvant therapy identified a single cut-off value of 
0.6. The cut-off value of 0.6 according to Dekker et al. [19] is quite 
different from that of this study of 0.21, and the difference can be 
partly explained by the assumption that preoperative adjuvant ther-
apy can increase the absolute value of the LNR by decreasing the 
number of non-metastatic lymph nodes [21]. However, the statis-
tically calculated cut-off values of 0.21, 0.32, and 0.61 in this study 
were within the range of the cut-off values in previous studies [12, 
23], so the cut-off values of the LNR to stratify the prognosis were 
within a certain range in spite of the diversity of the methodology 
used to determine them.
For the impact of the LNR on survival and systemic recurrence, 
the ratio was found to be a risk factor of death and systemic recur-
rence, unlike the correlation with local control, even after adjust-
ing various other clinical variables, including N staging, and this 
finding confirmed the results of previous studies [12-14]. It shows 
that the LNR is an important prognostic factor for death or recur-
rence and suggests the need for clinical efforts to reduce death and 
systemic recurrence in patients with a high LNR regardless of the 
current N staging. Moreover, the multivariate analysis of survival 
and systemic recurrence did not find a prognostic value of N stag-
ing in this study, which is consistent with the result of Ceelen et al. 
[22] that the LNR is a better prognostic factor than the number of 
metastatic lymph nodes in colorectal cancer and which is similar 
with those of Kim et al. [12] and Dekker et al. [19]. These results 
imply limitations of the existing N staging, which depends on only 
the number of metastatic lymph nodes, and suggest the need for a 
prognostic classification system based on LNR, refreflecting the 
numbers of collected lymph nodes.
Some reports demonstrated that the clinical significance of the 
LNR was not related with the numbers of the collected lymph node 
in colorectal cancer [12, 24], and others showed contrary results 
[10, 25]. According to a study of Kim et al. [12] on the LNR in rec-
tal cancer, the ratio had an oncologic impact regardless of the num-
ber of retrieved lymph nodes with a cutoff value of 17, and in the 
study of Rosenberg et al. [24], the correlation between LNR and 
survival in patients with a number of retrieved lymph nodes of 
less than 12 implied that the LNR was a clinical variable not much 
affected by the number of collected lymph nodes. In this study, 
because the cases with a number of collected lymph nodes of less 
than 12 was small we only performed a univariate analysis. How-
ever, the survival rate was significantly different by LNR, and this 
finding supports that of Rosenberg et al. [24].
The LNR divided into ranges based on cutoff values calculated 
Fig. 2. Survival curve for subgroups according to lymph node ratio 
(LNR) in patients with inadequate numbers of examined (P = 0.037).
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through recursive partitioning showed better prognostic predict-
ability than the current lymph node staging system in terms of 
death of and systemic recurrence in rectal cancer patients, and the 
oncologic significance of the LNR classification was observed even 
when the number of collected lymph nodes was less than 12. There-
fore, the LNR needs to be considered in any future staging system.
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